about
Electronegative LDL: a circulating modified LDL with a role in inflammationEffect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with heterozygous familial hypercholesterolemiaThe association of hypovitaminosis d with the metabolic syndrome is independent of the degree of obesity.Early intervention in the 3xTg-AD mice with an amyloid β-antibody fragment ameliorates first hallmarks of Alzheimer disease.Vitamin D concentrations in familial combined hyperlipidemia: effects of lipid lowering treatment.Inflammatory biomarkers in type 2 diabetic patients: effect of glycemic control and impact of LDL subfraction phenotype.Electronegative low-density lipoprotein. A link between apolipoprotein B misfolding, lipoprotein aggregation and proteoglycan binding.Modified lipoproteins as biomarkers of cardiovascular risk in diabetes mellitus.Electronegative LDL induces priming and inflammasome activation leading to IL-1β release in human monocytes and macrophages.Hypoxia worsens the impact of intracellular triglyceride accumulation promoted by electronegative low-density lipoprotein in cardiomyocytes by impairing perilipin 5 upregulation.Ceramide-enriched LDL induces cytokine release through TLR4 and CD14 in monocytes. Similarities with electronegative LDL.CD14 and TLR4 mediate cytokine release promoted by electronegative LDL in monocytes.Methionine-induced hyperhomocysteinemia impairs the antioxidant ability of high-density lipoproteins without reducing in vivo macrophage-specific reverse cholesterol transport.Thermal stability of human plasma electronegative low-density lipoprotein: A paradoxical behavior of low-density lipoprotein aggregation.Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized study.The Induction of Cytokine Release in Monocytes by Electronegative Low-Density Lipoprotein (LDL) Is Related to Its Higher Ceramide Content than Native LDL.2D-NMR reveals different populations of exposed lysine residues in the apoB-100 protein of electronegative and electropositive fractions of LDL particlesHDL and electronegative LDL exchange anti- and pro-inflammatory properties.Proteomic analysis of electronegative low-density lipoproteinAggregated electronegative low density lipoprotein in human plasma shows a high tendency toward phospholipolysis and particle fusion.Pro-inflammatory action of LDL(-) on mononuclear cells is counteracted by increased IL10 production.Immunochemical analysis of the electronegative LDL subfraction shows that abnormal N-terminal apolipoprotein B conformation is involved in increased binding to proteoglycans.Which cholesterol are we measuring with the Roche direct, homogeneous LDL-C Plus assay?LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy.Effect of glycemic optimization on electronegative low-density lipoprotein in diabetes: relation to nonenzymatic glycosylation and oxidative modification.Apo(B)-dependent dyslipidemic phenotypes in type 1 diabetic patients.Changes in low-density lipoprotein electronegativity and oxidizability after aerobic exercise are related to the increase in associated non-esterified fatty acids.Density distribution of electronegative LDL in normolipemic and hyperlipemic subjects.Mechanisms of HDL deficiency in mice overexpressing human apoA-II.Electronegative LDL of FH subjects: chemical characterization and induction of chemokine release from human endothelial cells.Response of oxidative stress biomarkers to a 16-week aerobic physical activity program, and to acute physical activity, in healthy young men and women.Postprandial lipidemia is normal in non-obese type 2 diabetic patients with relatively preserved insulin secretion.Effect of simvastatin in familial hypercholesterolemia on the affinity of electronegative low-density lipoprotein subfractions to the low-density lipoprotein receptor.Effects of multilayered bags vs ethylvinyl-acetate bags on oxidation of parenteral nutrition.Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.Increased lysophosphatidylcholine and non-esterified fatty acid content in LDL induces chemokine release in endothelial cells. Relationship with electronegative LDL.Impaired binding affinity of electronegative low-density lipoprotein (LDL) to the LDL receptor is related to nonesterified fatty acids and lysophosphatidylcholine content.Prevalence of metabolic syndrome among human immunodeficiency virus-infected subjects is widely influenced by the diagnostic criteria.Switching to basal-bolus insulin therapy is effective and safe in long-term type 2 diabetes patients inadequately controlled with other insulin regimens.Phytosterols inhibit the tumor growth and lipoprotein oxidizability induced by a high-fat diet in mice with inherited breast cancer.
P50
Q27015769-8CEF5A2E-6551-4CE4-AEF6-3804249ADBEAQ28373243-3BC7A722-9434-4509-9AF3-00BD45233D21Q36362197-33846C34-A667-411E-96BC-63D8E2E5EAE3Q37364350-923392FE-974B-4C08-BBF8-119122962194Q37525419-817336C0-2932-44BF-A6A6-EC5517971A4EQ37581259-AB4EE4D2-BBC4-4F29-B4CE-326C605859DBQ38042316-74480CB9-BC87-483E-BAAA-12AF62CBC775Q38094819-495BCE39-123D-4104-B9A1-9C0E663D5C89Q38839004-F073B8C8-6FB1-42BB-B8B3-F3CB698BECF2Q38861588-0D84CA7F-C63E-4D95-BD43-36539046444DQ39015509-984BC314-961B-4E6F-862F-12ACD9A5DA7CQ39121257-C36D24B2-E47D-4959-8D0E-A9D8D2E20588Q39141274-F81A584A-1E31-43B9-B2AE-97D80178056DQ41530349-6FB8224C-06DB-43C1-80CE-E1D229F7F826Q41583335-A9088567-7221-4E0B-9AF3-ADA98F41868CQ41618607-FC0D4E09-73BD-434C-8B0E-71B63675C193Q41864548-919C69BE-1248-4609-9A0F-81D952EB793DQ41953490-CDA12F28-531A-4FF7-B5F2-8E5D0900239CQ42377200-3EBF0D95-F1F8-436D-8757-743394EC178EQ42411907-16D0C6A9-BE14-4F4A-BBF9-F49A36D0677BQ42511349-05B8C9B6-2EC4-4258-9667-06C95008B2E7Q42571163-FF0F5F6C-D4F5-4CB0-8301-8CB7FD392A0DQ43516989-13B1824C-306E-45B7-803A-CA8C8BD4D207Q43572922-965D5677-D5CD-4134-80A5-7F523C49E648Q43666565-63E67033-666C-4A11-8966-F955303EDEDBQ43801137-B6CCBFD0-1866-43C2-891A-0DE6A846CEF0Q43833309-7A36A013-9DE6-41FB-89B4-B11F9A21DA9AQ43969252-A17F1477-B458-4987-9DC7-0CE2E07D6C1FQ44168323-CB9E34E5-3A6D-4802-AD1F-FADD327C3C1BQ44283323-91A9EF32-D8A6-45F8-8187-A5609EBDC521Q44485561-9AA27476-E072-46BF-B6C3-2D272C77906CQ44536729-53E9C188-2533-4F02-A827-6441D64D4C1FQ44768142-17D99075-A43F-4AE6-B41B-A52FC383FBE1Q44841026-F9F7B2DB-54F7-4AB7-9422-8ED9DDF70011Q45075496-D67263A6-2695-4920-A807-9BFD8ED0398BQ45142360-7D076A89-E06A-4A69-94C6-F72477D2F4F6Q45185008-E3AE38C2-F72F-44B8-BB6D-105DBC5359D1Q45366839-93794635-ECDA-46B1-A944-4DBDEC1002B0Q45398381-88F86F31-3543-4346-B36F-8FB35BBACF66Q45771241-7358948E-87C5-4E1F-BEA5-54F8A3B6A338
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jose Luis Sanchez-Quesada
@ast
Jose Luis Sanchez-Quesada
@en
Jose Luis Sanchez-Quesada
@es
Jose Luis Sanchez-Quesada
@nl
Jose Luis Sanchez-Quesada
@sl
type
label
Jose Luis Sanchez-Quesada
@ast
Jose Luis Sanchez-Quesada
@en
Jose Luis Sanchez-Quesada
@es
Jose Luis Sanchez-Quesada
@nl
Jose Luis Sanchez-Quesada
@sl
prefLabel
Jose Luis Sanchez-Quesada
@ast
Jose Luis Sanchez-Quesada
@en
Jose Luis Sanchez-Quesada
@es
Jose Luis Sanchez-Quesada
@nl
Jose Luis Sanchez-Quesada
@sl
P106
P21
P31
P496
0000-0003-0224-591X